Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chronic Pain Indications Will Be Harder To Come By, FDA Says

Executive Summary

A general chronic pain indication may elude Eli Lilly's Cymbalta near the finish line because FDA has changed its thinking about the evidence needed to support the claim

You may also be interested in...

Cymbalta Adds Musculoskeletal Pain Claim Despite Advisory Committee Concerns

Label for duloxetine's new use emphasizes that efficacy was shown only in patients with chronic lower back pain and osteoarthritis.

Cymbalta Chronic Pain Label: FDA Expresses Faith In Physicians' Judgment

FDA may place more faith in physician diligence to read updated labeling as it manages the risk for Eli Lilly's Cymbalta in some chronic pain indications

Cymbalta Could Get "Fairly Narrow Broad Indication" For Pain, FDA's Rappaport Says

Agency favors a claim for musculoskeletal pain, but advisory committee members suggest considering the cause, not just the location of the pain, in the indication.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts